Industrialization Center
We focus on applying for innovative biopharmaceutical patents, and also collaborate with hospitals to apply for clinical research projects on new biopharmaceutical technologies.
We also supplies clinical-grade products, accelerating the commercialization of new technologies such as cells and their derivatives.
Drug Pipeline
茵冠生物专注于开发针对神经系统疾病、退行性疾病等重大临床需求的创新生物药。目前已布局十余条药物管线，其中6 款细胞药物获 IND 受理，3款已取得国家药监局的临床试验默示许可。
Wingor Biotech has built a full-process technology platform from process development and quality research to large-scale production, and has a research and production team with more than 50% of its staff holding master's or doctoral degrees.The core technical team comes from top domestic and international institutions such as MIT, Stanford University, the Chinese Academy of Sciences, and the Chinese University of Hong Kong, and has extensive R&D and industrialization experience in the field of cell therapy.
Leveraging the team's expertise, the company will continue to expand its R&D pipeline and accelerate the clinical development, translation, and market launch of innovative stem cell and exosome drugs.
Drug Development Pipeline
National Medical Products Administration (CDE) Review and Public Notice
To date, Wingor has had 5 IND applications for stem cell new drugs accepted, of which 3 stem cell new drugs have obtained implied approval for clinical trials. Human umbilical cord mesenchymal stem cell injection (CXSL2200624) has been fully launched in Phase II clinical trials at eight national stroke centers, including Beijing Tiantan Hospital affiliated to Capital Medical University.
